8/6/2019 Feb2011ImmusanTexexecsummary

1/2

Intellectual PropertyImmusanT owns one and has exclusive licenses to three patents enabling diagnost

therapeutics based on the gluten peptides recognized by the disease-causing T cells in celiac

in the major global markets.

Executive SummaryImmusanT, Inc. is revolutionizing the diagnosis and treatment of celiac disease, which

approximately 1% of the population and currently has no pharmacological treatment. The Comharnessing the specificity of the immune reaction to gluten (protein in wheat, rye and ba

develop diagnostics and therapeutics. The Companys new treatment paradigm for celiac

leverages the immune response to gluten to isolate three toxic peptides responsible for the d

to the intestinal lining and for the alteration of nutritional absorption. ImmusanTs Founding S

along with his colleagues at Walter and Eliza Hall Research Institute and Oxford University

more than 200 celiac disease patients to elucidate the pathologic peptide epitopes. N

ImmusanTs peptide based immunotherapy, is designed to desensitize individuals with celiac

to the toxic effects of gluten allowing them to return to a normal diet, good health and im

quality of life.

ImmusanT Inc.

sanT, Inc. is a privately held emerging

chnology company focused on restoring

nce to gluten in celiac disease by harnessing

discoveries in immunology that improve

osis and treatment and return patients to a

al diet, good health and improved quality of

The Company, that acquired the technology

Australia based Nexpep Pty. Ltd., has a strong

ectual property position and foundational

e which provides the basis for their peptide-

immunotherapy and diagnostics.

sanT, Inc. is a Delaware Corporation with

s in Cambridge, MA.

on Statement

sanT seeks to restore tolerance to gluten in

nts with celiac disease.

ders & Team

J Williams, BS, RN. MBA

dent & CEO

nderson, MB, ChB, BmedSc, PhD FRACP

& CMO

ead, Autoimmunity & Transplantation

Walter and Eliza Hall Institute

y Matteodo

tific Advisors/Consultants

Tye Din, MB, BS, PhD FRACP

ific Consultant

r and Eliza Hall Institute, Melbourne, AU

Jabri, MD, PhD

r Scientific Advisor, Chicago, IL

ku Maki, MD, PhD

r Clinical Advisor

Binder, PhD

r Scientific/Technical Advisor

tific Advisory Board

nderson, MD, PhD

r and Eliza Hall Institute, Melbourne, AU

Binder, PhD

der, INOVA Diagnostics (acquired by Werfen

p)

Green, MD, Professor of Clinical Medicine,

mbia University, New York, NY

Jabri, MD, PhD

rsity of Chicago, Chicago, IL

n Kelly, MD, Professor of Medicine,

srael Hospital; Harvard University, Boston, MA

Lundin, MD, PhD, FACP (Hon)

oenterologist/Immunologist, Rikshospitalet

rsity of Oslo

ku Maki, MD, PhD, Professor of Pediatrics,

rsity of Tempere, Finland

h Murray, MD, Professor of Medicine, Mayo

Rochester, MN

elle Pietzak, MD, Pediatric Gastroenterologist,

ens Hospital

ngeles, CA

DDDOOOMMMIIINNNAAANNNCCCEEEIIINNNIIIMMMMMMUUUNNNOOOTTTHHHEEERRRAAAPPPYYY

One Broadway, 14th

Floor

Cambridge, MA 02142

617-401-2154 www.immusan

617-515-6755

Pathogenesis of Celiac Disease Central role of T-Cells

T-Cell Mediated Immune DiseaseCeliac disease is the first human immune disease for which there is comprehensive

understanding of the pathogenic T-cell response. ImmusanT has translated the

scientific discovery of immuno-dominant T-cell stimulatory gluten peptides into

valuable diagnostics and therapeutics for patients with celiac disease. It is believed

that upon repeated Nexvax2 dose administration, the number of gluten-specific T

cells capable of triggering a pro-inflammatory response will subside and regulatory

suppressor T cells will increase in number to establish tolerance to dietary gluten.

Tolerance is non-responsiveness to a specific antigen. Tolerance to an immune-

dominant gluten epitope is induced by administration of Nexvax2 peptides in the

absence of a second, T cell co-stimulatory, signal (danger signal). Nexvax2

peptides, delivered intradermally in small doses, re-programs/desensitizes the

disease causing T-cells. Because Nexvax2 is delivered in low doses without

adjuvant, T cell recognition will occur in a non-inflammatory environment and

responding CD4 T cells in celiac disease patients will be suppressed or undergo a

phenotypic change to a suppressor regulatory T cell phenotype.

ImmusanTs therapeutic focus - Peptide-based therapy

8/6/2019 Feb2011ImmusanTexexecsummary

2/2

arket Opportunityac Disease, also known as celiac sprue, is an inherited

oimmune disorder triggered by the consumption of foods

taining gluten, a cereal grain protein. It is a lifelong disease with

et in early childhood. The chronic inflammation of the intestine

this disease is caused by the immune response to gluten.

ecognized, celiac disease is a major contributor to poor

cational performance and failure to thrive in children. Untreated

ease is associated with other health conditions from IBS, bone

, anemia, chronic fatigue and diarrhea, to liver disease, infertility

cancers.

ac disease affects about 1% of the population globally (25.5M

ple; 7.5M in developed countries) and has historically been

er-diagnosed with no available drug therapy. The only option

most celiac patients is to eliminate gluten from their diet.

wever, that is not easy given that it is found in many foods. It has

n predicted that 50-60% of affected patients will be diagnosed in

eloped countries by 2019, creating a potential pharmaceutical

rket worth US$8 billion.

chnology Opportunity and Company Vision

celiac disease market is untapped and has significant growthential due to the high level unmet need. The recognition that

ac disease is an autoimmune disease (effect of gluten on the

stine is akin to what type 1, autoimmune, diabetes is to the

creas) that has serious long term complications if untreated, has

to increased awareness of this pathology.

musanT has a three prong strategy: increase awareness through

reach programs, enhanced diagnostics and biomarkers that

rove diagnosis and management of the disease, and a therapy

t directly targets the immunologic cause of this condition.

musanTs lead therapeutic vaccine, Nexvax2, is a combination of

ee proprietary peptides. ImmusanT has a commercial agreement

h INOVA Diagnostics to fund research aimed at discovering and

eloping new serology diagnostic screening tests for celiac

ease. In parallel ImmusanT is developing a novel functional T-cell

to diagnose and monitor optimal maintenance of immune

rance with peptide based therapy (Nexvax2).

musanTs lead product, Nexvax2, a therapeutic vaccine, is in

elopment and ready to advance to a Phase IIa clinical trial

ing completed:

Pre-clinical program

GMP drug manufacture

Pharmacokinetics and Toxicology conducted in rats Preclinical proof-of-concept in transgenic mouse model

Phase I First in human study: safety, tolerability & bioactivity

musanT will continue to advance their pipeline and expand the

ent portfolio internally and with academic collaborators. The

gress made in understanding, treating, preventing, and

gnosing celiac disease with peptides has major implications for

er autoimmune diseases and allergies. The Company intends to

tegically collaborate with leading pharmaceutical companies to

ance and expand their product portfolio.

Product Pipeline

ImmusanT Value Proposition:

Proprietary discovery platform for targetedimmunotherapy

Therapeutic and companion diagnostic andmonitoring tool

o Nexvax2 Phase I clinical trial completed Untapped growing market & high unmet need

o Potential market worth US $8 billion by2019

o No pharmacologic treatment currentlyavailable

Experienced management and scientific team Robust, blocking intellectual property estate Demonstrated manufacturability with two year

stability in cGMP facility

Demonstrated scalable formulation Seminal publications

One Broadway, 14th

Floor

Cambridge, MA 02142

617-515-6755

www.immusant.com